Clinical Research in Cardiology

, Volume 103, Issue 9, pp 701–710 | Cite as

Effect of bosentan therapy on ventricular and atrial function in adults with Eisenmenger syndrome. A prospective, multicenter study using conventional and Speckle tracking echocardiography

  • Mohamed Y. Abd El Rahman
  • Axel Rentzsch
  • Philipp Scherber
  • Siegrun Mebus
  • Oliver Miera
  • Günther Balling
  • Petra Böttler
  • Karl-Otto Dubowy
  • Birgit Farahwaschy
  • Alfred Hager
  • Joachim Kreuder
  • Brigitte Peters
  • Felix Berger
  • Ingram Schulze-Neick
  • Hashim Abdul-Khaliq
Original Paper

Abstract

Background

The effect of bosentan on the ventricular and atrial performance in patients with Eisenmenger syndrome is unclear. In adult patients with Eisenmenger syndrome, we aimed to evaluate the midterm effect of bosentan on physical exercise, ventricular and atrial function, and pulmonary hemodynamics.

Methods

Forty adult patients before and after 24 weeks bosentan therapy underwent 6 min walk test, two-dimensional speckle tracking echocardiography, plasma NT-proBNP measurement and cardiac catheterization.

Results

After 24 weeks, bosentan therapy an improvement was observed regarding the 6 min walk distance from a median (quartile 1–quartile 3) of 382.5 (312–430) to 450 (390–510) m (p = 0.0001), NT-proBNP from 527.5 (201–1,691.25) to 369 (179–1,246) pg/ml (p = 0.021), right ventricular mean longitudinal systolic strain from 18 (13–22) to 19 (14.5–25) % (p = 0.004), left ventricular mean longitudinal systolic strain from 16 (12–21) to 17 (16–22) % (p = 0.001), right atrial mean peak longitudinal strain from 26 (18–34) to 28 (22–34) % (p = 0.01) and right atrial mean peak contraction strain from 11 (8–16) to 13 (11–16) % (p = 0.005). The invasively obtained Qp:Qs and Rp:Rs did not significantly change under bosentan therapy.

Conclusions

In adult patients with Eisenmenger syndrome, bosentan therapy improves ventricular and atrial functions resulting in enhancement of physical exercise and reduction in the NT-proBNP level, while the pulmonary vascular resistance does not change substantially.

Keywords

Pulmonary arterial hypertension, echocardiography Myocardial contraction Remodeling 

Abbreviations

2-D STE

Two-dimensional speckle tracking echocardiography

6MWT

Six-minute walk test

CHD

Congenital heart defect

NT-proBNP

N-terminal pro-B-type natriuretic peptide

PACS

Peak atrial contraction strain

PAH

Pulmonary arterial hypertension

PALS

Peak atrial longitudinal strain

Qp:Qs

Pulmonary blood flow:systemic blood flow

ROI

Region of interest

Rp:Rs

Pulmonary resistance:systemic resistance

TAPSE

Tricuspid annular plane systolic excursion

Notes

Acknowledgments

The authors would like to acknowledge the collaboration and commitment of all the local investigators and their staff. Participating centers (listed in alphabetical order), in which patients have been included: Heart and Diabetes Center NRW, Bad Oeynhausen: D. Kececioglu, P. Beerbaum, S. Sarikouch, R. Schäffler. Deutsches Herzzentrum Berlin, Berlin: P. Ewert. Justus-Liebig University Giessen, Giessen: D. Schranz, R. Zimmermann. Saarland University Hospital, Homburg/Saar: A. Lindinger, J. Olchavary. Deutsches Herzzentrum Muenchen, Technische Universitaet Muenchen, Munich: J. Hess, H. Kaemmerer Consultant team in echocardiography: M. Vogel (Munich), M. Vogt (Munich). We are further indebted to Professor M. Böhm (Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, Saarland University Hospital) for his careful review of and valuable comments on the manuscript. Ms. Verena Materna, Koordinierungszentrum fuer Klinische Studien, Charité, Berlin for the organizing support. Ms. Brigitte Tüllmann, Koordinierungszentrum fuer Klinische Studien, Charité, Berlin for the monitoring work. Anne M. Gale, ELS, of Deutsches Herzzentrum Berlin, for editorial assistance. Ulrike Bauer, MD and Thomas Pickardt, Ph.D., Competence Network for Congenital Heart Defects, for the central research management. This work was supported by the Competence Network for Congenital Heart Defects funded by the Federal Ministry of Education and Research (BMBF), FKZ 01G10210, and by an unrestricted grant by Actelion Pharmaceuticals Deutschland GmbH.

Conflict of interest

The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

References

  1. 1.
    Lindinger A, Schwedler G, Hense HW (2010) Prevalence of congenital heart defects in newborns in Germany: results of the first registration year of the PAN Study (July 2006 to June 2007). Klin Padiatr 222:321–326PubMedCrossRefGoogle Scholar
  2. 2.
    Vongpatanasin W, Brickner ME, Hillis LD et al (1998) The Eisenmenger syndrome in adults. Ann Intern Med 128:745–755PubMedGoogle Scholar
  3. 3.
    Galie N, Beghetti M, Gatzoulis MA et al (2006) Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114:48–54PubMedCrossRefGoogle Scholar
  4. 4.
    Sitbon O, Beghetti M, Petit J et al (2006) Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest 36(Suppl 3):25–31PubMedCrossRefGoogle Scholar
  5. 5.
    Cameli M, Lisi M, Righini FM et al (2012) Novel echocardiographic techniques to assess left atrial size, anatomy and function. Cardiovasc Ultrasound 10:4PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117Google Scholar
  7. 7.
    Koestenberger M, Nagel B, Ravekes W et al (2011) Tricuspid annular plane systolic excursion and right ventricular ejection fraction in pediatric and adolescent patients with tetralogy of Fallot, patients with atrial septal defect, and age-matched normal subjects. Clin Res Cardiol 100:67–75PubMedGoogle Scholar
  8. 8.
    Eidem BW, Tei C, O’Leary PW et al (1998) Nongeometric quantitative assessment of right and left ventricular function: myocardial performance index in normal children and patients with Ebstein anomaly. J Am Soc Echocardiogr 11:849–856PubMedCrossRefGoogle Scholar
  9. 9.
    Geyer H, Caracciolo G, Abe H, et al (2010) Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr 23:351–69; quiz 453–5Google Scholar
  10. 10.
    Wilkinson JL (2001) Haemodynamic calculations in the catheter laboratory. Heart 85:113–120PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307–310PubMedCrossRefGoogle Scholar
  12. 12.
    Galie N, Beghetti M, Gatzoulis MA et al (2006) Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114(1):48–54. Epub 26 Jun 2006PubMedCrossRefGoogle Scholar
  13. 13.
    Gatzoulis MA, Beghetti M, Galie N et al (2008) Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 127:27–32PubMedCrossRefGoogle Scholar
  14. 14.
    Diller GP, Alonso-Gonzalez R, Kempny A et al (2012) B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart 98:736–742PubMedCrossRefGoogle Scholar
  15. 15.
    Moceri P, Dimopoulos K, Liodakis E, et al (2012) Echocardiographic predictors of outcome in eisenmenger syndrome. Circulation 126(12):1461–8. doi: 10.1161/CIRCULATIONAHA.112.091421. Epub 16 Aug 2012Google Scholar
  16. 16.
    Fogel MA, Rychik J (1998) Right ventricular function in congenital heart disease: pressure and volume overload lesions. Prog Cardiovasc Dis 40:343–356PubMedCrossRefGoogle Scholar
  17. 17.
    Hopkins WE (2005) The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 16:19–25PubMedCrossRefGoogle Scholar
  18. 18.
    Kaya MG, Lam YY, Erer B et al (2012) Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail 18:379–384PubMedCrossRefGoogle Scholar
  19. 19.
    Serino G, Guazzi M, Micheletti A et al (1041) Effect of bosentan on exercise capacity and clinical worsening in patients with dual down and Eisenmenger syndrome. Clin Med Insights Cardiol 2013(7):29–34. doi: 10.4137.37/CMCS10237. Epub 6 Feb 2013Google Scholar
  20. 20.
    Schulze-Neick I, Gilbert N, Ewert R et al (2005) Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 150:716PubMedCrossRefGoogle Scholar
  21. 21.
    Sharman JE, Brown J, Holland DJ et al (2009) Influence of altered blood rheology on ventricular–vascular response to exercise. Hypertension 54:1092–1098PubMedCrossRefGoogle Scholar
  22. 22.
    Parris RJ, Webb DJ (1997) The endothelin system in cardiovascular physiology and pathophysiology. Vasc Med 2:31–43PubMedGoogle Scholar
  23. 23.
    Iwanaga Y, Kihara Y, Hasegawa K et al (1998) Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 98:2065–2073PubMedCrossRefGoogle Scholar
  24. 24.
    Sakai S, Miyauchi T, Yamaguchi I (2000) Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure. Circulation 101:2849–2853PubMedCrossRefGoogle Scholar
  25. 25.
    Fraccarollo D, Hu K, Galuppo P, et al (1997) Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 96(11):3963–73Google Scholar
  26. 26.
    Mueller M, Rentzsch A, Hoetzer K et al (2010) Assessment of interventricular and right-intraventricular dyssynchrony in patients with surgically repaired tetralogy of Fallot by two-dimensional speckle tracking. Eur J Echocardiogr 11:786–792PubMedCrossRefGoogle Scholar
  27. 27.
    Hefke T, Zittermann A, Fuchs U, et al (2012) Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation. Thorac Cardiovasc Surg 60(1):26–34. doi: 10.1055/s-0030-1250726. Epub 22 Mar 2012Google Scholar
  28. 28.
    Trescher K, Bauer M, Dietl W, et al (2009) Improved myocardial protection in the failing heart by selective endothelin—a receptor blockade. J Thorac Cardiovasc Surg 137(4):1005–11, 1011e1. doi: 10.1016/jjtcvs200810037. Epub 12 Feb 2009Google Scholar
  29. 29.
    Teerlink JR (2002) Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail 8:124–127PubMedCrossRefGoogle Scholar
  30. 30.
    Magga J, Vuolteenaho O, Marttila M et al (1997) Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro. Circulation 96:3053–3062PubMedCrossRefGoogle Scholar
  31. 31.
    Bruneau BG, Piazza LA, de Bold AJ (1997) BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol 273:H2678–H2686PubMedGoogle Scholar
  32. 32.
    McDonagh TA, Holmer S, Raymond I et al (2004) NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 6:269–273PubMedCrossRefGoogle Scholar
  33. 33.
    Atkinson KJ, Fine DM, Thombs LA et al (2009) Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med 23:1190–1196PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Mohamed Y. Abd El Rahman
    • 1
    • 9
  • Axel Rentzsch
    • 1
  • Philipp Scherber
    • 1
  • Siegrun Mebus
    • 2
    • 3
  • Oliver Miera
    • 2
  • Günther Balling
    • 3
  • Petra Böttler
    • 4
  • Karl-Otto Dubowy
    • 5
  • Birgit Farahwaschy
    • 2
  • Alfred Hager
    • 3
  • Joachim Kreuder
    • 6
  • Brigitte Peters
    • 7
  • Felix Berger
    • 2
  • Ingram Schulze-Neick
    • 2
    • 8
  • Hashim Abdul-Khaliq
    • 1
  1. 1.Department of Pediatric CardiologySaarland University HospitalHomburg/SaarGermany
  2. 2.Department of Congenital Heart Disease/Pediatric CardiologyDeutsches HerzzentrumBerlinGermany
  3. 3.Department of Pediatric Cardiology and Congenital Heart Defects, German Heart Centre MunichTechnische Universitaet MuenchenMunichGermany
  4. 4.Department of Congenital Heart Defects/Pediatric CardiologyUniversity Hospital FreiburgFreiburgGermany
  5. 5.Center for Congenital Heart DefectsHeart and Diabetes Center NRWBad OeynhausenGermany
  6. 6.Pediatric Heart CenterJustus-Liebig University GiessenGiessenGermany
  7. 7.Department of Biometry and Medical InformaticsOtto von Guericke Universitaet MagdeburgMagdeburgGermany
  8. 8.UK Service for Pulmonary Hypertension in Children, Cardiac UnitGreat Ormond Street HospitalLondonUK
  9. 9.Department of Pediatrics and Pediatric CardiologyCairo UniversityCairoEgypt

Personalised recommendations